

1 **CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast**  
2 **Cancer**

3

4 Baitha Palanggatan Maggadani<sup>1\*</sup>, Kathleen Irena Junusmin<sup>2\*</sup>, Levana L. Sani<sup>2</sup>, Caroline Mahendra<sup>2</sup>,  
5 Margareta Amelia<sup>2</sup>, Gabriella<sup>2</sup>, Astrid Irwanto<sup>2,3</sup>, Harmita<sup>1</sup>, Yahdiana Harahap<sup>1,4</sup>, Samuel J.  
6 Haryono<sup>4,5†</sup>

7

8 <sup>1</sup>Faculty of Pharmacy, University of Indonesia, Jakarta, Indonesia

9 <sup>2</sup>Nalagenetics Pte Ltd, Singapore, Singapore

10 <sup>3</sup>Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore

11 <sup>4</sup>Indonesia Defense University, Bogor, West Java, Indonesia

12 <sup>5</sup>Surgical Oncology Division, SJH Initiative, MRCCC Siloam Hospital, Jakarta, Indonesia

13 \*These authors contributed equally to this work.

14 †Corresponding authors: samuelharyono@yahoo.com

15

16

17 **Abstract**

18 Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM) commonly prescribed for standard of  
19 care in estrogen receptor positive (ER+) breast cancer as an adjuvant therapy. Tamoxifen is  
20 metabolized by CYP2D6 into its active metabolite, endoxifen, which has been known to play an  
21 important role in reducing risk of ER+ breast cancer recurrence. *CYP2D6* is a highly polymorphic gene  
22 with more than 100 alleles. The phenotype of this gene is categorized into ultrarapid metabolizer  
23 (UM), normal metabolizer (NM), intermediate metabolizer (IM), and poor metabolizer (PM). Certain  
24 *CYP2D6* polymorphisms may cause reduced activity of this enzyme. Studies have found that reduced  
25 *CYP2D6* activity in IM and PM patients causes low efficacy of standard tamoxifen therapy. This study  
26 aims to observe the distribution of *CYP2D6* alleles and its correlation with endoxifen levels in  
27 Indonesian ER+ breast cancer patients. 151 patients who have received tamoxifen therapy for at  
28 least eight weeks were recruited prospectively. DNA and blood samples were collected with buccal  
29 swab and finger-prick methods, respectively. Genotyping was performed using the qPCR method  
30 while metabolite level measurement was performed using high performance liquid chromatography  
31 tandem mass spectrometry. We found that 40.67% of ER+ breast cancer patients recruited were IM.  
32 *CYP2D6*\*10 was the most abundant allele (0.288) in this population, and \*10/\*36 was the most  
33 frequently observed diplotype (0.236). Endoxifen levels between the NM-PM, NM-IM, and IM-PM  
34 were statistically significant ( $p$ -value =  $6.26 \times 10^{-5}$ ,  $9.12 \times 10^{-5}$ , and  $4.714 \times 10^{-3}$ , respectively), and  
35 dose increase of tamoxifen to 40 mg daily successfully increased endoxifen levels in IMs to a similar  
36 level with NMs at baseline. Given these findings, implementing pharmacogenomic testing of *CYP2D6*  
37 on ER+ breast cancer women who are about to undergo tamoxifen therapy may be beneficial to  
38 increase the likelihood of achieving expected endoxifen levels, thus better treatment efficacy.

39

40 Keywords: *CYP2D6* polymorphisms, endoxifen, pharmacogenomics, dose adjustment, allele  
41 frequency, phenotype distribution, metabolizer profile

42

43

44 **Introduction**

45

46 Estrogen receptor (ER) expression is the main indicator of potential responses to hormonal therapy,  
47 and approximately 70% of human breast cancers are hormone-dependent and ER+ (Lumachi *et al.*,  
48 2013). Hormone receptor-positive BC is associated with less aggressive features and a better  
49 prognosis because of the benefits from currently available endocrine therapy (Li *et al.*, 2020).  
50 Tamoxifen is the current standard of care for ER+ breast cancer adjuvant therapy. It works by  
51 binding to the estrogen receptor. The drug has been proven effective in reducing the number of  
52 recurrences especially in pre-menopausal women. About 170,000 tamoxifen prescriptions were filed  
53 in 2015 in Indonesia (IMS prescription data Indonesia, 2015), which implies that the usage of this  
54 drug has been prevalent in Indonesia to treat ER+ breast cancer.

55

56 Tamoxifen is a prodrug that needs to be metabolized to be active. However, half of the patients  
57 receiving tamoxifen may not have the full benefit of this drug due to the genetic polymorphisms that  
58 affect the function of the main enzyme metabolizing tamoxifen, CYP2D6 (Goetz *et al.*, 2008).  
59 Tamoxifen is metabolized to 4-hydroxy-*N*-desmethyltamoxifen (endoxifen), which has been proven  
60 to be an important contributor to the overall anticancer effect. Endoxifen is formed predominantly  
61 by CYP2D6 from *N*-desmethyltamoxifen, the most abundant metabolite (Dezentjé *et al.*, 2009).  
62 Endoxifen threshold value has been discovered to significantly impact breast cancer survival rates  
63 (Goetz *et al.*, 2005; Madlensky *et al.*, 2011). Upon years of follow up, those with endoxifen levels  
64 lower than 5.97 ng/mL had a 30% higher chance of having recurrence of breast cancer. Madlensky *et al.*  
65 further showed that being a CYP2D6 poor/intermediate metabolizer was associated with having a  
66 higher Body Mass Index (BMI), and consequently lower tamoxifen concentrations predicted risk for  
67 breast cancer recurrence (Madlensky *et al.*, 2011). Additionally, study has also shown that individual  
68 variability of CYP2D6 contributed 53% towards the ratio of *N*-desmethyltamoxifen and endoxifen,  
69 while combined other CYPs genetic factors (CYP2C9, CYP2C19, CYP3A5) and non-genetic factors (age,  
70 BMI) contributed to only 2.8% (Saladores *et al.*, 2015).

71

72 CYP2D6 gene that encodes Cytochrome P450 2D6 (CYP2D6) enzyme has more than 100 variants;  
73 some causing reduced activity, and others causing complete loss of function. The spectrum of the  
74 CYP2D6 enzymatic activity translates to different metabolizer profiles that are grouped into normal,  
75 ultrarapid, extensive, intermediate, and poor metabolizers (NM, UM, EM, IM, and PM, respectively),  
76 depending on how many reducing and/or loss of function alleles an individual carries. Asians and  
77 Africans were known to have up to 50% reduced activity alleles (Bradford, 2002). In Malays, Chinese  
78 and Indians, intermediate metabolizers occur in 35%, 45.38%, and 15%, respectively (Teh *et al.*,  
79 2001; Cui *et al.*, 2020; Goh *et al.*, 2017). Meanwhile, Caucasians were commonly extensive  
80 metabolizers (Chin *et al.*, 2016). CYP2D6 ultra-rapid and extensive metabolizers are able to take  
81 tamoxifen as indicated, according to the guidelines by Clinical Pharmacogenetics Implementation  
82 Consortium (CPIC) (Goetz *et al.*, 2018).

83

84 This study aims to observe the distribution of CYP2D6 genotypes and its correlation with endoxifen  
85 levels in ER+ breast cancer patients in Indonesia. CYP2D6 allele frequency and tamoxifen metabolite  
86 concentrations were observed. Patients who had CYP2D6 IM and PM phenotype profile were given  
87 recommendation to adjust tamoxifen dose to 40 mg daily, while patients who were clinically  
88 ineligible for tamoxifen dose increase according to clinical guidelines were switched to aromatase  
89 inhibitor. Our study observed the effectiveness of adjusting tamoxifen dosage as the first line of

90 action for patients who are clinically eligible to still consume the drug. Patients who received  
91 tamoxifen dose adjustment were monitored to ensure safety from potential side effects associated  
92 with tamoxifen.

93  
94

## 95 **Materials and Methods**

96

### 97 **Ethics Approval**

98 Institutional Review Board (IRB) approval was granted by MRCCC Siloam Hospitals Semanggi Ethics  
99 Review Committee (Jakarta, Indonesia) under IRB Reference Number  
100 001/EA/KEPKK/RSMRCCC/V/2019.

101

### 102 **Study Participants**

103 Patients were recruited from SJH Initiative, MRCCC Siloam Hospital Jakarta, Indonesia, from October  
104 2019 to April 2021 (n=151). The inclusion criteria of this study were as follows: (1) patient was  
105 diagnosed with ER+ breast cancer and (2) had consumed tamoxifen for at least eight weeks. Patients  
106 who fulfilled the inclusion criteria were offered to participate in the study and informed consent was  
107 obtained. Flow of recruitment steps is shown in Fig.1. Ethnicities reported in this study were self-  
108 reported, participants who identified with two or more ethnicities were categorized as mixed races.

109

### 110 **DNA Extraction**

111 Buccal swab sample was obtained from the patient for *CYP2D6* genotyping using ORAcollect•DNA  
112 OCR-100 (DNA Genotek) swab. Genomic DNA were extracted from buccal swab samples using  
113 Monarch Genomic DNA Purification Kit (NEB #T3010) following the manufacturer's instructions.  
114 Concentration of gDNA extracts were quantified using BioDrop spectrophotometer. Acceptance  
115 criteria to further process the DNA extract for genotyping, include: (1) total DNA yield  $\geq$  500 ng, (2)  
116 A260/280 ratio  $\geq$  1.75, and (3) A260/230 ratio  $\geq$  1.75.

117

### 118 ***CYP2D6* Genotyping**

119 *CYP2D6* genotyping was performed using Nala PGx Core™, a Lab-Developed Test genotyping panel  
120 consisting of four pharmacogenes: *CYP2D6*, *CYP2C19*, *CYP2C9* and *SLCO1B1* (Kothary *et al.*, 2021).  
121 *CYP2D6* variants that were genotyped in this test included rs35742686, rs59421388, rs3892097,  
122 rs5030656, rs72549352, rs5030655, rs28371725, rs16947, rs1065852, rs267608319, rs769258,  
123 rs5030865, rs1135840, total copy number of intron 2 and a detection for the presence of exon 9  
124 conversion. Genomic DNA extracts were diluted to 2ng/uL and added as template for Nala PGx  
125 Core™ qPCR runs on Bio-Rad CFX96 Touch™ Real-Time PCR Detection System. *CYP2D6* haplotypes,  
126 diplotypes and phenotypes were inferred by Nala Clinical Decision Support™ which is a class A  
127 medical device (Health Sciences Authority, Singapore) compatible with Nala PGx Core™ qPCR  
128 output.

129

### 130 **Measurement of Tamoxifen Metabolites**

131 Finger-prick blood sample was obtained using Volumetric Absorptive Microsampling (VAMS)  
132 technique. VAMS extraction was performed in methanol by sonication-assisted extraction method  
133 for 25 minutes after 2 hours of VAMS drying. Separation was carried out using Acquity UPLC BEH C<sub>18</sub>  
134 column (2.1 x 100 mm; 1.7  $\mu$ m), with a flow rate of 0.2 mL/minute, and the mobile phase gradient of

135 formic acid 0.1% combined with formic acid 0.1% in acetonitrile for 5 minutes. The UPLC-MS/MS  
136 Waters Xevo TQD Triple Quadrupole with MassLynx Software controller (Waters, Milford, USA) was  
137 employed in metabolites measurement. Mass detection was carried out utilizing Triple Quadrupole  
138 (TQD) with Multiple Reaction Monitoring (MRM) analysis modes and an electrospray ionization  
139 source using positive mode. The method was developed in the Bioavailability and Bioequivalence  
140 Laboratory of Universitas Indonesia and validated according to FDA and EMA guidelines (Maggadani  
141 *et al.*, 2021). The multiple reaction monitoring (MRM) value were set at  $m/z$  372.28>72.22 for TAM;  
142 374.29>58.22 for END; 388.29>72.19 for 4-HT; 358.22>58.09 for NDT; and 260.20>116.20 for  
143 propranolol as the internal standard.

144

#### 145 **Patient Follow Up**

146 Patients with IM or PM *CYP2D6* profile who were clinically ineligible for tamoxifen dose increase  
147 were switched to aromatase inhibitor (n=18) and were not followed up further for side effects  
148 monitoring and metabolite levels changes. This group of patients were determined based on clinical  
149 judgement according to the available guidelines by The National Surgical Oncologist Organization  
150 and Ministry of Health in Indonesia (Komite Penanggulangan Kanker Nasional, n.d.), National  
151 Comprehensive Cancer Network (NCCN, 2021), and British Columbia Cancer Agency (Kennecke *et al.*,  
152 2006). IM or PM patients who did not have any contraindications to tamoxifen were given a  
153 recommendation to adjust its dose to 40 mg/day (n=26), while UMs and NMs remained with the  
154 normal 20 mg/day recommended dose (n=81). Tamoxifen metabolites levels in the study  
155 participants who were given 40 mg/day of tamoxifen were measured eight weeks post dose  
156 adjustment. Endocrine symptoms which were possible side effects of tamoxifen therapy were also  
157 monitored in patients who received tamoxifen dose adjustment to 40 mg daily using the FACT-ES  
158 questionnaire (Fallowfield *et al.*, 1999).

159

#### 160 **Data Analysis**

161 Data and statistical analysis were performed using Microsoft® Excel® for Microsoft 365 and R version  
162 4.0.3. Deviation from Hardy-Weinberg equilibrium was performed on the haplotype frequencies  
163 using the chi-square statistical test, where Bonferonni correction was applied to determine the  $p$ -  
164 value threshold for significant deviation. Analysis of Variance (ANOVA) test was used to see if  
165 metabolite levels distribution at baseline were statistically different across all metabolites, followed  
166 by a paired T-test between each pair of metabolites when significance was found. Distribution of  
167 metabolite levels before and after dose adjustment was compared using a T-test, and the same test  
168 was used to compare the distribution of metabolite levels in IMs post-dose adjustment against NMs  
169 (baseline). Concerning symptoms related to endocrine therapy post-dose adjustment on IMs were  
170 compared against NMs. Chi-square test was performed per symptom to check for the difference  
171 between the two groups.

172

173

## 174 **Results**

175

### 176 **Demographics of Study Participants**

177 Table 1 shows that out of the 151 participants included in the study, most of the participants were  
178 50 years old and below, making up 78.15% of the total respondents. This proportion was followed by  
179 participants between 51-59 years old (17.88%). A small number of older participants with age  $\geq 60$

180 years (3.97%) was also observed. The majority of participants consisted of individuals with Chinese  
181 (33.77%) and Javanese (25.17%) descents. Participants with multiethnic and multiracial descents  
182 were also observed (16.56%), followed by small numbers of other Indonesian ethnicities such as  
183 Sundanese (5.96%), Batak (5.3%), Betawi (3.31%), Minang (3.31%), Ambonese (1.32%), and South  
184 Sumatran (1.32%). Among these participants, 47.33% underwent lumpectomy (also known as breast  
185 conserving surgery), while 44% underwent mastectomy (total removal of breast tissue). Aside from  
186 surgical intervention, 66.67% of these participants underwent adjuvant post-operative radiotherapy  
187 and 50% underwent adjuvant chemotherapy. Respondents were mostly still in the early stage of  
188 breast cancer during the time of recruitment, with proportion as follows: stage I (27.15%), stage IIa  
189 (23.84%), and stage IIb (13.91%). Participants who were enrolled to the study and were in the later  
190 stage of breast cancer were also observed, with proportion as follows: stage IIIa (7.95%), IIIb  
191 (5.96%), and stage IV (7.95%). About half of the study participants (50.33%) were enrolled within 12  
192 months after initial diagnosis of breast cancer. The other participants were enrolled within 13-24  
193 (15.23%), 25-36 (13.25%), and 37-48 (9.27%) months after initial diagnosis, with a proportion of  
194 patients who had been diagnosed for longer than four years ago (10.6%). According to the available  
195 biopsy data, 44.37% of the participants had moderately differentiated tumors, while 27.81% and  
196 11.92% of the participants had poorly and moderately differentiated tumors, respectively.

197

#### 198 **CYP2D6 Haplotype Distribution**

199 All haplotypes observed were in Hardy-Weinberg equilibrium ( $p$ -value > 0.005). *CYP2D6*\*10 was  
200 found to be the most abundant haplotype in the population (0.288, n=83/288), followed by  
201 *CYP2D6*\*36 (0.253, n=73/288). Compared to PharmGKB database of the East Asian population, \*10  
202 was lower, but \*36 was much higher in this study compared to the frequency reported by the  
203 database, 0.012 (Fig. 2). The reference haplotype *CYP2D6*\*1 was observed with frequency of 0.233  
204 (n=67/288), and other haplotypes were also observed with frequencies as follows: \*2 (0.128,  
205 n=37/288), \*41 (0.045, n=13/288), \*5 (0.021, n=6/288), \*3 (0.014, n=4/288), \*39 (0.007, n=2/288),  
206 \*4A (0.007, n=2/288), and \*14 (0.003, n=1/288).

207

#### 208 **CYP2D6 Diplotype Distribution**

209 Our study demonstrated \*10/\*36 (0.236, n=34/144) as the most abundant diplotype in the  
210 population, followed by \*1/\*36 (0.132, n=19/144) (Table 2). Other diplotypes that were observed in  
211 this study with diplotype frequencies between 0.1-0.05 were as follows: \*2/\*10 (0.097, n=14/144),  
212 \*1/\*1 (0.09, n=13/144), \*2/\*36 (0.083, n=12/144), \*1/\*10 (0.076, n=11/144), and \*10/\*10 (0.065,  
213 n=9/144). Other diplotypes observed had frequencies lower than 0.05. The list of relevant diplotypes  
214 can be found in Table 2.

215

#### 216 **CYP2D6 Phenotypes Distribution**

217 Our findings show that among the 150 patients genotyped, 40.67% (n=61/150) were IMs. This is  
218 much higher than the current known global prevalence of IMs which is between 0.4-11%. The  
219 frequency of NMs observed in this study was 54% (n=81/150). PMs were also observed in the  
220 population at 1.33% (n=61/150) (Fig. 3). Ultrarapid metabolizers were not observed among the  
221 participants in this study. Distribution of the *CYP2D6* phenotypes among major ethnicities in this  
222 study's participants showed a higher proportion of IMs in Chinese (56.86%, n=29/51) compared to  
223 other ethnicities such as Javanese (23.68%, n=9/38). PM was observed in the Javanese group with  
224 2.63% frequency (n=1). Ethnicities with participant counts less than 10 were grouped as others, due

225 to inefficient number of samples to conclude allele frequencies (Supplementary Table 2). Mixed  
226 races group showed 37.5% proportion of IM (n=6/16). Among all major ethnicity groups, only  
227 Chinese ethnicity group displayed a greater proportion of IM compared to NM (Fig. 4).

228

### 229 **Tamoxifen Metabolite Concentration**

230 Endoxifen levels among the three metabolizers were significantly different ( $p$ -value = 0.00307, Table  
231 3). The rest of the metabolites did not show any statistically significant distribution among  
232 phenotypes ( $p$ -value = 0.964, 0.461, 0.443 for tamoxifen, 4-hydroxytamoxifen, and N-  
233 desmethyltamoxifen, respectively). T-test performed on endoxifen levels for each phenotype pair  
234 displayed significant difference among all phenotype pairs ( $p$ -value =  $6.26 \times 10^{-5}$ ,  $9.12 \times 10^{-5}$ , and  
235  $4.714 \times 10^{-3}$  for NM-PM, NM-IM, and IM-PM, respectively), demonstrating distinction of endoxifen  
236 levels across different phenotypes (Fig. 5). After grouping the endoxifen levels into five quintiles, it  
237 was revealed that the highest number of IMs fall into the lowest quintile while the highest number  
238 of NMs fall into the highest quintile (Supplementary Table 1).

239

### 240 **Follow Up Action Following PGx Testing**

241 Among 66 IM or PM participants who were given the recommendation to modify their medication  
242 based on their *CYP2D6* phenotype (Fig. 6), 18 patients (27.3%, n=18/66) had their medication  
243 switched to aromatase inhibitors based on clinical guidelines or certain medical procedure such as  
244 post Ovarian Function Suppression (OFS) endocrine therapy. 38 patients (57.6%, n=38/66) were  
245 recommended by their physicians to adjust their tamoxifen dosage from 20 mg daily to 40 mg daily,  
246 while the remaining participants who did not follow the genotype-guided recommendation either  
247 passed away or experienced recurrence, thus they had to dismiss their adjuvant therapy temporarily  
248 (15.2%, n=10/66).

249

### 250 **Metabolite Levels Post Dose Adjustment**

251 26 patients who took 40 mg of tamoxifen daily for two months all experienced an increase in  
252 metabolite levels. After dose adjustment, the range of tamoxifen metabolites increased as follows:  
253 tamoxifen levels from 14.22-210.39 ng/mL to 80.59-254.96 ng/mL; endoxifen levels from 3.17-22.97  
254 ng/mL to 7.68-23.36 ng/mL; 4-hydroxytamoxifen levels from 1.5-9.31 ng/mL to 3.34-12.99 ng/mL,  
255 and N-desmethyltamoxifen levels from 77.61-337.29 ng/mL to 236.8-501.9 ng/mL (Fig. 7).  
256 Metabolite levels before and after dose adjustment had  $p$ -value < 0.05, demonstrating statistically  
257 significant differences before and after dose adjustment across all metabolites.

258

259 The metabolite levels in IMs (n=26) post dose adjustment were compared against NMs (n=81) as the  
260 baseline, showing indeed a significant difference between the two groups ( $p$ -value < 0.05) for all  
261 metabolites except endoxifen ( $p$ -value = 0.4135). The distribution of endoxifen levels in IMs post  
262 dose adjustment (7.68-23.36 ng/mL) were similar to the endoxifen levels in NMs (3.55 - 34.77  
263 ng/mL) at baseline (Fig. 8).

264

### 265 **Side Effects Post Dose Adjustment**

266 The most commonly reported treatment side effects in IMs were weight gain and mood swings,  
267 which are related to endocrine therapy. These occurred in 65.83% of participants who received 40  
268 mg of tamoxifen daily (n=17/26). Other common symptoms related to hormonal changes were also  
269 observed in participants who received 40 mg of tamoxifen daily such as hotflush (50%, n=13/26),

270 cold sweats (19.23%, n=5/26), night sweats (26.92%, n=7/26), vaginal discharge (42.31%, n=11/26),  
271 vaginal itching or irritation (15.38%, n=4/26), vaginal bleeding or spotting (23.08%, n=6/26), vaginal  
272 dryness (11.54%, n=3/26), pain or discomfort during intercourse (3.85%, n=1/26), lost interest in sex  
273 (15.38%, n=4/26), breast sensitivity or tenderness (53.85%, n=14/26), and irritability (61.54%,  
274 n=16/26). Other symptoms that might be related to endocrine therapy were also observed, such as  
275 lightheaded/dizziness (34.62%, n=9/26), vomiting (3.85%, n=1/26), headaches (53.85%, n=14/26),  
276 bloating (46.15%, n=12/26), and pain in joints (50%, n=13/26). No post-dose adjustment participants  
277 reported diarrhea.

278

279 The most commonly reported side effect in the patient group that took 20 mg of tamoxifen daily was  
280 mood swings, occurring in 74.19% of the respondents (n=23/31), although they did not receive any  
281 treatment adjustments. Other common symptoms related to hormonal changes were also observed  
282 in NM participants such as hotflush (35.48%, n=11/31), cold sweats (12.9%, n=4/31), night sweats  
283 (29.03%, n=9/31), vaginal discharge (38.71%, n=12/31), vaginal itching or irritation (22.58%, n=7/31),  
284 vaginal bleeding or spotting (16.13%, n=5/31), vaginal dryness (32.26%, n=10/31), pain or discomfort  
285 during intercourse (51.61%, n=16/31), lost interest in sex (64.52%, n=20/31), breast sensitivity or  
286 tenderness (41.94%, n=13/31), and irritability (58.06%, n=18/31). Other symptoms that might be  
287 related to endocrine therapy were also observed, such as lightheaded/dizziness (35.48%, n=11/31),  
288 vomiting (6.45%, n=2/31), diarrhea (3.23%, n=1/31), headaches (29.03%, n=9/31), bloating (38.71%,  
289 n=12/31), and pain in joints 67.74%, n=21/31).

290

291 T-test performed between symptoms experienced by participants receiving dose adjustment to 40  
292 mg daily and participants taking 20 mg daily resulted in two symptoms (pain or discomfort during  
293 intercourse and lost interest in sex) with statistical significance between the two groups. Other than  
294 these two symptoms, the other symptoms did not have significant difference among the two groups,  
295 indicating that dose escalation up to 40 mg daily did not increase potential toxicity or side effects  
296 (Table 4). Thrombophlebitis, thrombosis, endometriosis, and endometrial cancer were also some of  
297 the most concerning side effects of tamoxifen (American Society of Clinical Oncology, 2009;  
298 Bergman *et al.*, 2000), and none of these side effects were observed in the observed population.

299

300

## 301 Discussion

302

303 This study aimed to observe the distribution of *CYP2D6* genotypes and phenotypes across  
304 Indonesian women diagnosed with ER+ breast cancer who were taking tamoxifen as adjuvant  
305 therapy. Our respondents were mostly of Chinese and Javanese descent. Chinese ethnicity group in  
306 this study's population showed a higher proportion of intermediate metabolizers, while the Javanese  
307 ethnicity group was dominated by normal metabolizers (Fig. 4). The proportion of IMs in Indonesian  
308 Chinese included in this study was higher than a similar study conducted on Han Chinese population,  
309 which was 45.38% (Cui *et al.*, 2020). Ethnicity differences may play a role in contributing to the  
310 differences between the findings in this study and other similar studies conducted in different  
311 populations. Caucasians may have a higher proportion of normal metabolizers compared to other  
312 races/ethnicities though the frequencies are slightly varied depending on the geographical location  
313 where the studies were conducted (Zafra-Ceres *et al.*, 2013; Hertz *et al.*, 2016; Helland *et al.*, 2017).

314

315 Our results reported *CYP2D6\*10* as the most common *CYP2D6* haplotype. Some studies have  
316 suggested that this allele increases the risk of breast cancer recurrence for those taking tamoxifen as  
317 adjuvant therapy (Kiyotani *et al.*, 2008). A study conducted in the Han Chinese population showed  
318 that the frequency of *CYP2D6\*10* in this population was 45.7% (Lan *et al.*, 2018), higher than the  
319 frequency of *CYP2D6\*10* observed in this study (28.8%). Another important highlight was the  
320 relatively high frequency of *\*36* allele observed in this study (0.253) compared to the observed  
321 frequency in the PharmGKB database (0.012). Compared to other Asian population, a study  
322 conducted in Hong Kong population also recorded a relatively high frequency of *CYP2D6\*36* which is  
323 34.1% (Chan *et al.*, 2019). Although some *\*36* allele contributed to normal metabolizer status  
324 profile, our study observed *\*10/\*36* diplotype as the diplotype with highest frequency (0.236), and  
325 this diplotype translates as IM phenotype which suggested that *\*36* may play an important role in  
326 constructing IM phenotype profiles in Indonesian population. These findings suggested that  
327 Indonesian population might be at higher risk of experiencing ineffectiveness of tamoxifen therapy.  
328 This was also supported by the high proportion of *CYP2D6* IMs (40.67%) compared to other studies  
329 conducted in different populations (Madlensky *et al.*, 2011). This was also much higher than the  
330 current known global prevalence of IMs which is between 0.4-11% (Gaedigk *et al.*, 2017). Even so,  
331 some populations also reported a higher proportion of IMs (Hertz *et al.*, 2016), suggesting that  
332 different populations composed of various ethnicities may play a role in genetic make-up differences  
333 of *CYP2D6*. Compared to our result, a similar study conducted in Thailand population showed a  
334 relatively high frequency compared to the global prevalence (29.1%), implying that East Asian  
335 population may have relatively higher frequency of IM (Sukasem *et al.*, 2012). The frequency of NMs  
336 observed in this study (54%) was also lower than the current known global prevalence which is  
337 between 67-90% (Gaedigk *et al.*, 2017).

338

339 Different metabolites of tamoxifen and their levels were a predictor of tamoxifen's efficacy,  
340 especially endoxifen levels. Lower endoxifen levels in IMs may indicate lower efficacy of tamoxifen in  
341 preventing recurrence (Madlensky *et al.*, 2011). Compared to the study conducted by Madlensky *et al.*  
342 (2011), the average value of endoxifen levels in IMs observed in this study was higher. The  
343 previous study observed the average endoxifen level of IMs to be 8.1 ng/mL while this study  
344 recorded an average at 9.6 ng/mL. However, a study conducted in Swedish population found a range  
345 of endoxifen level between 2.3-16 ng/mL (Thorén *et al.*, 2021), while another study conducted in  
346 Singaporean population displayed a range between 1.74-42.8 ng/mL (Lim *et al.*, 2011). These  
347 suggested that studies conducted with similar interventions but in different populations may find  
348 different ranges of metabolite levels.

349

350 In this study, we recommended IMs and PMs to adjust their tamoxifen dosage or switch prescription  
351 to aromatase inhibitors for patients that were clinically ineligible for consumption of tamoxifen  
352 (Goetz *et al.*, 2018). We specifically monitored patients who received tamoxifen dose adjustment to  
353 40 mg daily, and our results have shown that participants who received 40 mg of tamoxifen daily all  
354 experienced a significant increase across all metabolite levels, including endoxifen levels. This  
355 suggested that increasing tamoxifen intake can elevate endoxifen levels as expected and may play a  
356 role in increasing the therapeutic effect of tamoxifen. The distribution of endoxifen level in IMs post  
357 dose adjustment were similar to the endoxifen level in NMs at the baseline, suggesting that

358 increasing tamoxifen dosage to 40 mg daily for IM participants had successfully let IM participants  
359 reach the expected endoxifen levels as observed in NMs.

360

361 Gynecological side effects similar to menopausal symptoms such as hot flushes, vaginal dryness, and  
362 endometriosis were commonly observed in patients taking tamoxifen (Mourits *et al.*, 2001).  
363 According to the survey for endocrine symptoms in this study, most participants experienced mild to  
364 moderate degree of endocrine symptoms. Despite some of the IM respondents in this study who  
365 received dose increase reporting experiencing hot flush, no respondents reported dismissing  
366 tamoxifen intake due to the symptom. Hot flush was also commonly reported in patients taking the  
367 standard dose of tamoxifen therapy (Kligman & Younus, 2010; Mortimer *et al.*, 2008), which means  
368 increasing tamoxifen dose does not change side effects of the drug distinctly. Thrombophlebitis,  
369 thrombosis, endometriosis, and endometrial cancer were also some of the most concerning side  
370 effects of tamoxifen (American Society of Clinical Oncology, 2009; Bergman *et al.*, 2000), since they  
371 fatally affect patients' quality of life and life expectancy. None of these side effects were observed in  
372 the observed population, but this might also be underestimated due to the short period of follow up  
373 on this study. Other studies who have tried to observe tamoxifen side effects occurring in patients  
374 with dose increase also concluded that increasing tamoxifen dose did not result in toxicity or short-  
375 term increase in side effects (Hertz *et al.*, 2016; Dezentjé *et al.*, 2015).

376

377 These findings concluded that tamoxifen dose adjustment is beneficial enough to increase potential  
378 therapeutic effect through the increase of metabolite levels, with no fatal side effects recorded.  
379 Although CPIC guideline recommended the first course of action to switch to aromatase inhibitors,  
380 our finding demonstrated that tamoxifen dose adjustment is adequate. This is favorable due to: 1)  
381 the higher likelihood of potential side effects from aromatase inhibitors than tamoxifen (Garreau *et al.*,  
382 2006), 2) lower price of tamoxifen than aromatase inhibitors to allow cost-effectiveness in  
383 periodical prescriptions throughout the period of adjuvant therapy.

384

### 385 **Limitations**

386 One of the several limitations of this study was the subjective measurement of side effects using  
387 FACT-ES. Due to the subjective nature of answering the survey and rating each symptom, each  
388 respondent may have their own perspective on symptom intensity and severity. Another limitation  
389 of this study was the relatively short amount of follow up actions observation, which may lead to  
390 underestimating the number of certain side effects that may not immediately show up after  
391 tamoxifen therapy initiation.

392

### 393 **Conclusion**

394 Our study has shown a considerable proportion of *CYP2D6* intermediate metabolizers (40.67%) in  
395 Indonesian women with ER+ breast cancer consuming tamoxifen, suggesting possible ineffectiveness  
396 of tamoxifen therapy to prevent recurrence. This was also supported by the significant difference of  
397 the endoxifen levels between normal and intermediate metabolizers in our study participants. Dose  
398 adjustment of tamoxifen was proven to elevate the level of endoxifen, the metabolite responsible  
399 for the anticancer effect of tamoxifen. Increase of tamoxifen intake to 40 mg daily in IM patients did  
400 not show any significant or fatal side effects. Given these findings, implementing pharmacogenomic  
401 testing of *CYP2D6* on ER+ breast cancer women who are about to undergo adjuvant therapy with

402 tamoxifen may be beneficial to avoid possible inefficacy of tamoxifen in preventing breast cancer  
403 recurrence.

404

### 405 **Future Work**

406 Our study has validated the need and benefit of pharmacokinetics and pharmacogenomics analysis,  
407 further follow up on the same breast cancer patient cohort is required to better understand the  
408 effect and benefits of *CYP2D6* genotyping and endoxifen level measurement towards clinical  
409 outcomes such as relapse rate, disease-free survival, and overall survival. Future work may involve  
410 monitoring these patients for a longer period of duration when potential side effects were reported  
411 previously to appear (Lorizio *et al.*, 2012). Monitoring this cohort may be useful to prove the benefit  
412 of *CYP2D6* genotyping towards the clinical outcomes of tamoxifen therapy in Indonesian population.

413

### 414 **Acknowledgements**

415 We would like to thank SJH Initiatives and MRCCC Siloam Hospital for their major contribution in  
416 patient recruitment, notably Dismas Chaspuri, MD; Arif Winata, MD; and Rachmat Nijkuluw, MD.  
417 We would also like to extend our gratitude to The Bioavailability and Bioequivalence Laboratory of  
418 Universitas Indonesia, PT Nalagenetik Riset Indonesia, and School of Medicine and Health Sciences,  
419 Atma Jaya Catholic University of Indonesia for their support in facilitating sample processing  
420 activities. We would like to acknowledge all participants who have voluntarily provided their  
421 specimen and time to be involved in this study.

422

### 423 **Authors Contribution**

424 BPM, LLS, AI, YH, H, and SJH contributed to study design. KIJ, MA, and SJH contributed to patient  
425 recruitment. BPM and G performed laboratory experiments. KIJ and MA were responsible for patient  
426 data management. BPM, KIJ, CM, and AI performed data analysis. KIJ and CM contributed to  
427 manuscript writing with supervision from LLS, AI, BPM, and SJH.

428

### 429 **Funding**

430 This research was funded by the University of Indonesia's 2019-2020 research grant. Additional  
431 research expenses were also funded by Nalagenetics Pte Ltd, Singapore and PT Nalagenetik Riset  
432 Indonesia.

433

### 434 **Conflict of Interest**

435 KIJ, LLS, CM, MA, G, and AI are employees of Nalagenetics Pte Ltd, Singapore.

436

### 437 **Data Availability Statement**

438 The data that supports the findings of this study are available as supplementary materials. Any  
439 additional data is available from the corresponding author upon reasonable request.

440

### 441 **References**

442 American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of  
443 Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast

- 444 Cancer Risk Reduction. (2009). *Journal of oncology practice*, 5(4), 196–199.  
445 <https://doi.org/10.1200/JOP.0948502>  
446
- 447 Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000). Risk  
448 and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer  
449 Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. *Lancet*  
450 (*London, England*), 356(9233), 881–887. [https://doi.org/10.1016/s0140-6736\(00\)02677-5](https://doi.org/10.1016/s0140-6736(00)02677-5)  
451
- 452 Bradford L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their  
453 descendants. *Pharmacogenomics*, 3(2), 229–243. <https://doi.org/10.1517/14622416.3.2.229>  
454
- 455 Chan, W., Li, M. S., Sundaram, S. K., Tomlinson, B., Cheung, P. Y., & Tzang, C. H. (2019). CYP2D6 allele  
456 frequencies, copy number variants, and tandems in the population of Hong Kong. *Journal of clinical*  
457 *laboratory analysis*, 33(1), e22634. <https://doi.org/10.1002/jcla.22634>  
458
- 459 Chin, F. W., Chan, S. C., Abdul Rahman, S., Noor Akmal, S., & Rosli, R. (2016). CYP2D6 Genetic  
460 Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients. *The*  
461 *breast journal*, 22(1), 54–62. <https://doi.org/10.1111/tbj.12518>  
462
- 463 Cui, Y., Yan, H., Su, Y., Wang, L., Lu, T., Zhang, D., & Yue, W. (2020). CYP2D6 Genotype-Based Dose  
464 Recommendations for Risperidone in Asian People. *Frontiers in pharmacology*, 11, 936.  
465 <https://doi.org/10.3389/fphar.2020.00936>  
466
- 467 Dezentjé, V. O., Guchelaar, H. J., Nortier, J. W., van de Velde, C. J., & Gelderblom, H. (2009). Clinical  
468 implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. *Clinical cancer research*  
469 *: an official journal of the American Association for Cancer Research*, 15(1), 15–21.  
470 <https://doi.org/10.1158/1078-0432.CCR-08-2006>  
471
- 472 Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten, T., Vree, R.,  
473 Maartense, E., Smorenburg, C. H., Putter, H., Dieudonné, A. S., Neven, P., Van de Velde, C. J., Nortier,  
474 J. W., & Guchelaar, H. J. (2015). CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation  
475 increases endoxifen serum concentrations without increasing side effects. *Breast cancer research*  
476 *and treatment*, 153(3), 583–590. <https://doi.org/10.1007/s10549-015-3562-5>  
477
- 478 Fallowfield, L. J., Leaity, S. K., Howell, A., Benson, S., & Cella, D. (1999). Assessment of quality of life  
479 in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom  
480 subscale for the FACT-B. *Breast cancer research and treatment*, 55(2), 189–199.  
481 <https://doi.org/10.1023/a:1006263818115>  
482
- 483 Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M. *et al.* (2017). Prediction of CYP2D6 phenotype from  
484 genotype across world populations. *Genet Med* 19, 69–76 (2017).  
485 <https://doi.org/10.1038/gim.2016.80>  
486

- 487 Garreau, J. R., Delamelena, T., Walts, D., Karamlou, K., & Johnson, N. (2006). Side effects of  
488 aromatase inhibitors versus tamoxifen: the patients' perspective. *American journal of surgery*,  
489 *192*(4), 496–498. <https://doi.org/10.1016/j.amjsurg.2006.06.018>  
490
- 491 Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., Symmans,  
492 W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., Gaedigk, A., van Schaik, R. H., Ingle, J. N., Caudle, K.  
493 E., & Klein, T. E. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for  
494 CYP2D6 and Tamoxifen Therapy. *Clinical pharmacology and therapeutics*, *103*(5), 770–777.  
495 <https://doi.org/10.1002/cpt.1007>  
496
- 497 Goetz, M. P., Kamal, A., & Ames, M. M. (2008). Tamoxifen pharmacogenomics: the role of CYP2D6 as  
498 a predictor of drug response. *Clinical pharmacology and therapeutics*, *83*(1), 160–166.  
499 <https://doi.org/10.1038/sj.cpt.6100367>  
500
- 501 Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C.,  
502 Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A., & Ingle, J. N. (2005).  
503 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy  
504 and hot flashes. *Journal of clinical oncology : official journal of the American Society of Clinical*  
505 *Oncology*, *23*(36), 9312–9318. <https://doi.org/10.1200/JCO.2005.03.3266>  
506
- 507 Goh, L. L., Lim, C. W., Sim, W. C., Toh, L. X., & Leong, K. P. (2017). Analysis of Genetic Variation in  
508 CYP450 Genes for Clinical Implementation. *PLoS one*, *12*(1), e0169233.  
509 <https://doi.org/10.1371/journal.pone.0169233>  
510
- 511 Helland, T., Henne, N., Bifulco, E., Naume, B., Borgen, E., Kristensen, V. N., Kvaløy, J. T., Lash, T. L.,  
512 Alnæs, G., van Schaik, R. H., Janssen, E., Hustad, S., Lien, E. A., Mellgren, G., & Sjøiland, H. (2017).  
513 Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly  
514 treated breast cancer patients. *Breast cancer research : BCR*, *19*(1), 125.  
515 <https://doi.org/10.1186/s13058-017-0916-4>  
516
- 517 Hertz, D. L., Deal, A., Ibrahim, J. G., Walko, C. M., Weck, K. E., Anderson, S., Magrinat, G., Olajide, O.,  
518 Moore, S., Raab, R., Carrizosa, D. R., Corso, S., Schwartz, G., Graham, M., Peppercorn, J. M., Jones, D.  
519 R., Desta, Z., Flockhart, D. A., Evans, J. P., McLeod, H. L., ... Irvin, W. J., Jr (2016). Tamoxifen Dose  
520 Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations  
521 Without Increasing Toxicity. *The oncologist*, *21*(7), 795–803.  
522 <https://doi.org/10.1634/theoncologist.2015-0480>  
523
- 524 IMS prescription data Indonesia, 2015  
525
- 526 Kennecke, H. F., Ellard, S., O'Reilly, S., Gelmon, K. A., (2006). New guidelines for treatment of early  
527 hormone-positive breast cancer with tamoxifen and aromatase inhibitors. *BC Medical Journal*, *48*(3):  
528 121-126.  
529
- 530 Kiyotani, K., Mushiroda, T., Sasa, M., Bando, Y., Sumitomo, I., Hosono, N., Kubo, M., Nakamura, Y., &  
531 Zembutsu, H. (2008). Impact of CYP2D6\*10 on recurrence-free survival in breast cancer patients

- 532 receiving adjuvant tamoxifen therapy. *Cancer science*, 99(5), 995–999.
- 533 <https://doi.org/10.1111/j.1349-7006.2008.00780.x>
- 534
- 535 Kligman, L., & Younus, J. (2010). Management of hot flashes in women with breast cancer. *Current*
- 536 *oncology (Toronto, Ont.)*, 17(1), 81–86. <https://doi.org/10.3747/co.v17i1.473>
- 537
- 538 Komite Penanggulangan Kanker Nasional. (n.d.). *Panduan Penatalaksanaan Kanker Payudara*.
- 539 Retrieved from <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
- 540
- 541 Kothary, A. S., Mahendra, C., Tan, M., Min Tan, E. J., Hong Yi, J. P., Gabriella, Hui Jocelyn, T. X.,
- 542 Haruman, J. S., Lee, C. K., Yan, B., & Irwanto, A. (2021). Validation of a multi-gene qPCR-based
- 543 pharmacogenomics panel across major ethnic groups in Singapore and Indonesia. *MedRxiv*.
- 544 Published. <https://doi.org/10.1101/2021.05.10.21256948>
- 545
- 546 Lan, B., Ma, F., Zhai, X., Li, Q., Chen, S., Wang, J., Fan, Y., Luo, Y., Cai, R., Yuan, P., Zhang, P., Li, Q., &
- 547 Xu, B. (2018). The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in
- 548 adjuvant endocrine therapy of breast cancer patients in Chinese Han population. *International*
- 549 *journal of cancer*, 143(1), 184–189. <https://doi.org/10.1002/ijc.31291>
- 550
- 551 Li, Y., Yang, D., Yin, X., Zhang, X., Huang, J., Wu, Y., Wang, M., Yi, Z., Li, H., Li, H., & Ren, G. (2020).
- 552 Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single
- 553 Hormone Receptor-Positive Breast Cancer. *JAMA network open*, 3(1), e1918160.
- 554 <https://doi.org/10.1001/jamanetworkopen.2019.18160>
- 555
- 556 Lorizio, W., Wu, A. H., Beattie, M. S., Rugo, H., Tchu, S., Kerlikowske, K., & Ziv, E. (2012). Clinical and
- 557 biomarker predictors of side effects from tamoxifen. *Breast cancer research and treatment*, 132(3),
- 558 1107–1118. <https://doi.org/10.1007/s10549-011-1893-4>
- 559
- 560 Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., & Basso, S. M. (2013). Treatment of estrogen
- 561 receptor-positive breast cancer. *Current medicinal chemistry*, 20(5), 596–604.
- 562 <https://doi.org/10.2174/092986713804999303>
- 563
- 564 Maggadani, B. P., Harmita, Haryono, S. J., Rinaldi, M. R., & Harahap Y. (2021). Volumetric Absorptive
- 565 Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen
- 566 and N-Desmethyltamoxifen in Breast Cancer Patients. *Drug Des Devel Ther.* 2021;15:2417-2430.
- 567 <https://doi.org/10.2147/DDDT.S286409>
- 568
- 569 Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., Nikoloff, D. M., Hillman, G.,
- 570 Fontecha, M. R., Lawrence, H. J., Parker, B. A., Wu, A. H., & Pierce, J. P. (2011). Tamoxifen metabolite
- 571 concentrations, CYP2D6 genotype, and breast cancer outcomes. *Clinical pharmacology and*
- 572 *therapeutics*, 89(5), 718–725. <https://doi.org/10.1038/clpt.2011.32>
- 573
- 574 Mortimer, J. E., Flatt, S. W., Parker, B. A., Gold, E. B., Wasserman, L., Natarajan, L., Pierce, J. P., &
- 575 WHEL Study Group (2008). Tamoxifen, hot flashes and recurrence in breast cancer. *Breast cancer*
- 576 *research and treatment*, 108(3), 421–426. <https://doi.org/10.1007/s10549-007-9612-x>

577

578 Mourits, M. J., De Vries, E. G., Willemse, P. H., Ten Hoor, K. A., Hollema, H., & Van der Zee, A. G.  
579 (2001). Tamoxifen treatment and gynecologic side effects: a review. *Obstetrics and gynecology*, 97(5  
580 Pt 2), 855–866. [https://doi.org/10.1016/s0029-7844\(00\)01196-0](https://doi.org/10.1016/s0029-7844(00)01196-0)

581

582 National Comprehensive Cancer Network. (2021). *Breast cancer (version 4.2021)*. Retrieved from  
583 [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)

584

585 Saladores, P., Mürdter, T., Eccles, D., Chowbay, B., Zgheib, N. K., Winter, S., Ganchev, B., Eccles, B.,  
586 Gerty, S., Tfayli, A., Lim, J. S., Yap, Y. S., Ng, R. C., Wong, N. S., Dent, R., Habbal, M. Z., Schaeffeler, E.,  
587 Eichelbaum, M., Schroth, W., Schwab, M., ... Brauch, H. (2015). Tamoxifen metabolism predicts drug  
588 concentrations and outcome in premenopausal patients with early breast cancer. *The*  
589 *pharmacogenomics journal*, 15(1), 84–94. <https://doi.org/10.1038/tpj.2014.34>

590

591 Sukasem, C., Sirachainan, E., Chamnanphon, M., Pechatanan, K., Sirisinha, T., Ativitavas, T.,  
592 Panvichian, R., Ratanatharathorn, V., Trachu, N., & Chantratita, W. (2012). Impact of CYP2D6  
593 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in  
594 Thailand. *Asian Pacific journal of cancer prevention : APJCP*, 13(9), 4549–4553.  
595 <https://doi.org/10.7314/apjcp.2012.13.9.4549>

596

597 Thorén, L., Lindh, J. D., Ackehed, G., Kringen, M. K., Hall, P., Bergh, J., Molden, E., Margolin, S., &  
598 Eliasson, E. (2021). Impairment of endoxifen formation in tamoxifen-treated premenopausal breast  
599 cancer patients carrying reduced-function CYP2D6 alleles. *British journal of clinical pharmacology*,  
600 87(3), 1243–1252. <https://doi.org/10.1111/bcp.14500>

601

602 Teh, L. K., Ismail, R., Yusoff, R., Hussein, A., Isa, M. N., & Rahman, A. R. (2001). Heterogeneity of the  
603 CYP2D6 gene among Malays in Malaysia. *Journal of clinical pharmacy and therapeutics*, 26(3), 205–  
604 211. <https://doi.org/10.1046/j.1365-2710.2001.00347.x>

605

606 van de Velde, C. J., Verma, S., van Nes, J. G., Masterman, C., & Pritchard, K. I. (2010). Switching from  
607 tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with  
608 early breast cancer. *Cancer treatment reviews*, 36(1), 54–62.  
609 <https://doi.org/10.1016/j.ctrv.2009.10.003>

610

611 Zafra-Ceres, M., de Haro, T., Farez-Vidal, E., Blancas, I., Bandres, F., de Dueñas, E. M., Ochoa-Aranda,  
612 E., Gomez-Capilla, J. A., & Gomez-Llorente, C. (2013). Influence of CYP2D6 polymorphisms on serum  
613 levels of tamoxifen metabolites in Spanish women with breast cancer. *International journal of*  
614 *medical sciences*, 10(7), 932–937. <https://doi.org/10.7150/ijms.5708>

615

## 616 Tables

617

618 **Table 1. Study respondents demographics**

<u>Age</u>	n	%
<40	23	15.33%

40-49	88	58.67%
50-59	33	22.00%
>59	6	4.00%
<b><u>Menopausal status</u></b>		
Premenopausal	54	36.00%
Post-menopausal	96	64.00%
<b><u>Menarche</u></b>		
7-11 years old	24	16.00%
12-13 years old	83	55.33%
>13 years old	37	24.67%
NA*	6	4.00%
<b><u>Race</u></b>		
Ambon	2	1.32%
Batak	8	5.30%
Betawi	5	3.31%
Chinese	51	33.77%
Javanese	38	25.17%
Minangkabau	5	3.31%
Palembang	2	1.32%
Sunda	9	5.96%
Mixed races	25	16.56%
NA*	6	3.97%
<b><u>Past Breast Cancer Treatment</u></b>		
Lumpectomy	7	4.67%
Lumpectomy, chemotherapy	2	1.33%
Lumpectomy, radiotherapy	34	22.67%
Lumpectomy, chemotherapy, radiotherapy	23	15.33%
Mastectomy	18	12.00%

Mastectomy, chemotherapy	16	10.67%
Mastectomy, radiotherapy	5	3.33%
Mastectomy, radiotherapy, chemotherapy	25	16.67%
Mastectomy, lumpectomy, radiotherapy, chemotherapy	2	1.33%
Radiotherapy	9	6.00%
Chemotherapy	2	1.33%
Radiotherapy, chemotherapy	5	3.33%
NA*	2	1.33%
<b><u>Stage</u></b>		
ST 0	0	0%
ST I	34	22.67%
ST IIA	48	32.00%
ST IIB	17	11.33%
ST IIIA	9	6.00%
ST IIIB	11	7.33%
ST IIIC	2	1.33%
ST IV	12	8.00%
NA*	17	11.33%
<b><u>Time Recruited from Diagnosis (Months)</u></b>		
1-12	76	50.33%
13-24	23	15.23%
25-36	20	13.25%
37-48	14	9.27%
>48	16	10.60%
NA*	1	0.66%
<b><u>Tumor Grade</u></b>		
Well differentiated / Grade	18	11.92%

1		
Moderately differentiated / Grade 2	67	44.37%
Poorly differentiated / Grade 3	42	27.81%
NA*	23	15.33%

619 \*NA: data not available

620

621

622

**Table 2. CYP2D6 diplotype frequencies observed**

Diplotype	Phenotype	Counts (N total = 144)	Frequency
*10/*36	Intermediate Metabolizer	34	0.236
*1/*36	Normal Metabolizer	19	0.132
*2/*10	Normal Metabolizer	14	0.097
*1/*1	Normal Metabolizer	13	0.090
*2/*36	Normal Metabolizer	12	0.083
*1/*10	Normal Metabolizer	11	0.076
*10/*10	Normal Metabolizer	9	0.065
Others <sup>^</sup>		41	0.222

623

<sup>^</sup>Other diplotypes were observed with frequency less than 0.05, these diplotypes were \*1/\*2,

624

\*36/\*41, \*1/\*41, \*10/\*41, \*1/\*5, \*2/\*2, \*3/\*36, \*5/\*10, \*5/\*41, \*1/\*3, \*1/\*4A, \*14/\*36, \*2/\*3,

625

\*2/\*39, \*2/\*41, \*36/\*39, and \*4A/\*10

626

627

628

**Table 3. Summary of metabolite levels in relation to CYP2D6 metabolizer profiles**

CYP2D6 Phenotype		Concentration (ng/mL)			
		Tamoxifen	Endoxifen	4OH-tam	ND-tam
Normal Metabolizer (N = 81)	Mean	82.30	13.17	3.30	224.86
	SD	35.21	6.62	1.46	56.83
	Median	77.46	11.98	3.07	240.59

	Range	31.22 - 170.82	3.55 - 34.77	1.5 - 7.66	80.63 - 321.88
Intermediate Metabolizer (N = 61)	Mean	85.62	9.59	3.60	233.70
	SD	37.20	4.35	1.67	58.01
	Median	81.72	8.33	3.27	241.55
	Range	14.22 - 210.39	3.17 - 22.97	1.5 - 9.31	77.61 - 337.29
Poor Metabolizer (N = 2)	Mean	91.49	4.52	3.24	276.45
	SD	33.93	0.83	0.26	90.44
	Median	91.49	4.52	3.24	276.45
	Range	67.49 - 115.48	3.94 - 5.11	3.06 - 3.43	212.5 - 340.41
<i>p</i> -value (ANOVA)		0.964	0.00307*	0.461	0.443

629

630

631 **Table 4. Number and percentage of patient responses related to adverse events in FACT-ES post**  
 632 **eight weeks after dose adjustment.** \*Statistically significant *p*-value was observed

Symptoms	NM participants who received 20 mg of tamoxifen daily (N = 31)		IM participants who received 40 mg of tamoxifen daily (N = 22)		<i>p</i> -value
	Patients reported side effect (n)	Patients reported side effect (%)	Patients reported side effect (n)	Patients reported side effect (%)	
Hot Flashes	11	35.48%	13	50.00%	0.269361
Cold Sweats	4	12.90%	5	19.23%	0.717648
Night sweats	9	29.03%	7	26.92%	0.86249
Vaginal discharge	12	38.71%	11	42.31%	0.777297
Vaginal itching/irritation	7	22.58%	4	15.38%	0.492987
Vaginal bleeding or spotting	5	16.13%	6	23.08%	0.507122


Vaginal dryness	10	32.26%	3	11.54%	0.063252
Pain or discomfort with intercourse*	16	51.61%	1	3.85%	$8.48 \times 10^{-5}$ *
Lost interest in sex	20	64.52%	4	15.38%	0.005461*
Weight gain	20	64.52%	17	65.38%	1
Lightheaded (dizzy)	11	35.48%	9	34.62%	1
Vomiting	2	6.45%	1	3.85%	1
Diarrhea	1	3.23%	0	0.00%	1
Headaches	9	29.03%	14	53.85%	0.057089
Bloating	12	38.71%	12	46.15%	0.571608
Breast sensitivity/tenderness	13	41.94%	14	53.85%	0.371093
Mood swings	23	74.19%	17	65.38%	0.470842
Irritable	18	58.06%	16	61.54%	0.791337
Pain in joints	21	67.74%	13	50.00%	0.173783

633 \*Statistically significant *p*-values were observed between IMs who have received tamoxifen dose  
 634 adjustment and NMs who took the standard dose

635


636 **Figures**

637




638  
639  
640  
641

**Fig.1 | Research flow diagram.**




642  
643  
644  
645

**Fig.2 | Distribution of haplotype frequencies among Indonesian breast cancer patients. n=288**




646  
647  
648  
649

**Fig.3 | Distribution of phenotype frequencies among Indonesian breast cancer patients. n=144**




650  
651  
652  
653  
654

**Fig.4 | Distribution of phenotype frequencies per major ethnicity among Indonesian breast cancer patients. n=151**




655


656 **Fig.5 | Distribution of endoxifen levels for each observed phenotype at the baseline.** Normal  
657 metabolizer/NM (n=81), Intermediate metabolizer/IM (n=61), Poor Metabolizer/PM (n=2)  
658  
659



660  
661 **Fig.6 | Distribution of the different follow up actions selected by doctors after patient's CYP2D6**  
662 **profile was characterized through genetic testing.** n=66  
663  
664



665  
666 **Fig.7 | Metabolite levels before and after dose adjustment for IM patients.** a.) Tamoxifen, b.)  
667 endoxifen, c.) 4-hydroxytamoxifen, d.) N-desmethyltamoxifen. \*Statistically significant *p*-values  
668 were observed between metabolites before and after dose adjustment, n=26  
669  
670



671 **Fig. 8 | Metabolite levels in IMs after dose adjustment compared to NMs at the baseline.** a.)  
 672 Tamoxifen, b.) endoxifen, c.) 4-hydroxytamoxifen, d.) N-desmethyltamoxifen. \*Statistically  
 673 significant *p*-values were observed, n=81 (NMs), n=26 (IMs). Endoxifen levels in IMs post dose  
 674 adjustment were statistically similar to NMs at the baseline.  
 675  
 676

677 **Supplementary**

678

679 **Supplementary Table 1. Number of NMs and IMs in each quintile group of endoxifen measured at**  
 680 **baseline.**

Quintiles	NMs	IMs	PMs
Q1	8	17	2
Q2	12	12	0
Q3	19	11	0
Q4	15	12	0
Q5	23	5	0

681

682 **Supplementary Table 2. Number of participants in each ethnicity observed. n=150**

Ethnicity	n
Chinese	51
Javanese	38

Others	Ambon	2
	Batak	8
	Betawi	5
	Makassar	1
	Manado	1
	Melayu	1
	Minangkabau	5
	Nias	1
	Padang	1
	Palembang	2
	West Sumatera	1
	Sunda	9
	Timor Leste	1
	Tolaki / Sulawesi	1
Toraja	1	
Multiethnic	16	
NA*	6	

683 \*NA: data not available

684

685